Anaphore Names Grayson as New CEO

Luke Timmerman6/20/11

Anaphore, the San Diego-based developer of novel protein drugs, said today it has named Paul Grayson as its new CEO. Grayson is the former CEO of San Diego-based Fate Therapeutics and was a managing director at Sanderling Ventures. He replaces Kathy Bowdish, who will remain a consultant to Anaphore. Last year, Anaphore formed a partnership with Japan-based Mitsubishi Tanabe that could be worth more than $110 million over time.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @